Top

Published in:

01-08-2020 | Systemic Lupus Erythematosus | Review

Implications of COVID-19 in pediatric rheumatology

Authors: Ezgi Deniz Batu, Seza Özen

Published in: Rheumatology International | Issue 8/2020

Abstract

COVID-19 (coronavirus disease 2019) pandemic caused by SARS-CoV-2, is a global public health issue threatening millions of lives worldwide. Although the infection is mild in most of the affected individuals, it may cause severe clinical manifestations such as acute respiratory distress syndrome or cytokine storm leading to death. Children are affected less, and most experience a milder disease. As rheumatologists, we deal with the uncontrolled response of the immune system, and most of the drugs we use are either immune modulators or immunosuppressants. Thus, the rheumatologists participate in the multidisciplinary management of COVID-19 patients. On the other hand, our patients with rheumatic diseases constitute a vulnerable group in this pandemic. In this review, a systematic literature search was conducted utilizing MEDLINE/PubMed and Scopus databases, and 231 COVID-19 patients with rheumatic diseases have been identified. Only one of these patients was a child. Among these, 9 (3.9%) died due to COVID-19. In light of the current data, the aspects of COVID-19 resembling rheumatic diseases, the possible reasons for why children are affected less severely, the hypothetic role of available vaccines in preventing COVID-19, the unique position of patients with rheumatic diseases in this pandemic, and the use of anti-rheumatic drugs in COVID-19 treatment are discussed.

Available only for authorised users

Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi HW, Lo SK, Chan KH, Poon VK, Chan WM, Ip JD, Cai JP, Cheng VC, Chen H, Hui CK, Yuen KY (2020) A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395:514–523. https://doi.org/10.1016/S0140-6736(20)30154-9 CrossRefPubMedPubMedCentral

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497–506. https://doi.org/10.1016/S0140-6736(20)30183-5 CrossRefPubMedPubMedCentral

Rothan HA, Byrareddy SN (2020) The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 109:102433. https://doi.org/10.1016/j.jaut.2020.102433 CrossRefPubMedPubMedCentral

Licciardi F, Giani T, Baldini L, Favalli EG, Caporali R, Cimaz R (2020) COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country. Pediatr Rheumatol Online J 18:35. https://doi.org/10.1186/s12969-020-00422-z CrossRefPubMedPubMedCentral

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395:565–574. https://doi.org/10.1016/S0140-6736(20)30251-8 CrossRefPubMedPubMedCentral

Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579:270–273. https://doi.org/10.1038/s41586-020-2012-7 CrossRefPubMedPubMedCentral

Chen J, Subbarao K (2007) The Immunobiology of SARS*. Annu Rev Immunol 25:443–472. https://doi.org/10.1146/annurev.immunol.25.022106.141706 CrossRefPubMed

Du Toit A (2016) Viral infection: changing sides to get in. Nat Rev Microbiol 14:476–477. https://doi.org/10.1038/nrmicro.2016.98 CrossRefPubMed

Hedrich CM (2020) COVID-19—considerations for the paediatric rheumatologist. Clin Immunol 214:108420. https://doi.org/10.1016/j.clim.2020.108420 CrossRefPubMedPubMedCentral

10.

Channappanavar R, Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, Perlman S (2016) Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe 19:181–193. https://doi.org/10.1016/j.chom.2016.01.007 CrossRefPubMedPubMedCentral

11.

Cameron MJ, Ran L, Xu L, Danesh A, Bermejo-Martin JF, Cameron CM, Muller MP, Gold WL, Richardson SE, Poutanen SM, Willey BM, DeVries ME, Fang Y, Seneviratne C, Bosinger SE, Persad D, Wilkinson P, Greller LD, Somogyi R, Humar A, Keshavjee S, Louie M, Loeb MB, Brunton J, McGeer AJ, Canadian SRN, Kelvin DJ (2007) Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J Virol 81:8692–8706. https://doi.org/10.1128/JVI.00527-07 CrossRefPubMedPubMedCentral

12.

Ye Q, Wang B, Mao J (2020) The pathogenesis and treatment of the `Cytokine Storm' in COVID-19. J Infect. https://doi.org/10.1016/j.jinf.2020.03.037 CrossRefPubMedPubMedCentral

13.

Liu L, Wei Q, Lin Q, Fang J, Wang H, Kwok H, Tang H, Nishiura K, Peng J, Tan Z, Wu T, Cheung KW, Chan KH, Alvarez X, Qin C, Lackner A, Perlman S, Yuen KY, Chen Z (2019) Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight. https://doi.org/10.1172/jci.insight.123158 CrossRefPubMedPubMedCentral

14.

Fu Y, Cheng Y, Wu Y (2020) Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virol Sin. https://doi.org/10.1007/s12250-020-00207-4 CrossRefPubMedPubMedCentral

15.

Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, Wang J, Qin Y, Zhang X, Yan X, Zeng X, Zhang S (2020) The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clin Immunol 214:108393. https://doi.org/10.1016/j.clim.2020.108393 CrossRefPubMedPubMedCentral

16.

Rockx B, Baas T, Zornetzer GA, Haagmans B, Sheahan T, Frieman M, Dyer MD, Teal TH, Proll S, van den Brand J, Baric R, Katze MG (2009) Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection. J Virol 83:7062–7074. https://doi.org/10.1128/JVI.00127-09 CrossRefPubMedPubMedCentral

17.

Smits SL, de Lang A, van den Brand JM, Leijten LM, Eijkemans MJ, van Amerongen G, Kuiken T, Andeweg AC, Osterhaus AD, Haagmans BL (2010) Exacerbated innate host response to SARS-CoV in aged non-human primates. PLoS Pathog 6:e1000756. https://doi.org/10.1371/journal.ppat.1000756 CrossRefPubMedPubMedCentral

18.

Misra DP, Agarwal V, Gasparyan AY, Zimba O (2020) Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol. https://doi.org/10.1007/s10067-020-05073-9 CrossRefPubMedPubMedCentral

19.

Henderson LA, Canna SW, Schulert GS, Volpi S, Lee PY, Kernan KF, Caricchio R, Mahmud S, Hazen MM, Halyabar O, Hoyt KJ, Han J, Grom AA, Gattorno M, Ravelli A, de Benedetti F, Behrens EM, Cron RQ, Nigrovic PA (2020) On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheumatol. https://doi.org/10.1002/art.41285 CrossRefPubMedPubMedCentral

20.

Vardavas CI, Nikitara K (2020) COVID-19 and smoking: a systematic review of the evidence. Tob Induc Dis 18:20. https://doi.org/10.18332/tid/119324 CrossRefPubMedPubMedCentral

21.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395:1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3 CrossRefPubMedPubMedCentral

22.

Haslak F, Yildiz M, Adrovic A, Barut K, Kasapcopur O (2020) Childhood rheumatic diseases and COVID-19 pandemic: an intriguing linkage and a New Horizon. Balkan Med J. https://doi.org/10.4274/balkanmedj.galenos.2020.2020.4.43 CrossRefPubMedPubMedCentral

23.

Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, Tong S (2020) Epidemiology of COVID-19 among children in China. Pediatrics. https://doi.org/10.1542/peds.2020-0702 CrossRefPubMedPubMedCentral

24.

Wu Z, McGoogan JM (2020) Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA. https://doi.org/10.1001/jama.2020.2648 CrossRefPubMedPubMedCentral

25.

D'Antiga L (2020) Coronaviruses and immunosuppressed patients: the facts during the third epidemic. Liver Transpl. https://doi.org/10.1002/lt.25756 CrossRefPubMedPubMedCentral

26.

Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409–1417. https://doi.org/10.1007/s00296-011-1999-3 CrossRefPubMed

27.

Favalli EG, Agape E, Caporali R (2020) Incidence and clinical course of COVID-19 in patients with connective tissue diseases: a descriptive observational analysis. J Rheumatol. https://doi.org/10.3899/jrheum.200507 CrossRefPubMed

28.

Gianfrancesco MA, Hyrich KL, Gossec L, Strangfeld A, Carmona L, Mateus EF, Sufka P, Grainger R, Wallace Z, Bhana S, Sirotich E, Liew J, Hausmann JS, Costello W, Robinson P, Machado PM, Yazdany J, Committee C-GRAS (2020) Rheumatic disease and COVID-19: initial data from the COVID-19 global rheumatology alliance provider registries. Lancet Rheumatol. https://doi.org/10.1016/S2665-9913(20)30095-3 CrossRefPubMedPubMedCentral

29.

Guilpain P, Le Bihan C, Foulongne V, Taourel P, Pansu N, Maria ATJ, Jung B, Larcher R, Klouche K, Le Moing V (2020) Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-217549 CrossRefPubMed

30.

Han Y, Jiang M, Xia D, He L, Lv X, Liao X, Meng J (2020) COVID-19 in a patient with long-term use of glucocorticoids: a study of a familial cluster. Clin Immunol 214:108413. https://doi.org/10.1016/j.clim.2020.108413 CrossRefPubMedPubMedCentral

31.

Jones VG, Mills M, Suarez D, Hogan CA, Yeh D, Bradley Segal J, Nguyen EL, Barsh GR, Maskatia S, Mathew R (2020) COVID-19 and kawasaki disease: novel virus and novel case. Hosp Pediatr. https://doi.org/10.1542/hpeds.2020-0123 CrossRefPubMed

32.

Mathian A, Mahevas M, Rohmer J, Roumier M, Cohen-Aubart F, Amador-Borrero B, Barrelet A, Chauvet C, Chazal T, Delahousse M, Devaux M, Euvrard R, Fadlallah J, Florens N, Haroche J, Hie M, Juillard L, Lhote R, Maillet T, Richard-Colmant G, Palluy JB, Pha M, Perard L, Remy P, Riviere E, Sene D, Seve P, Morelot-Panzini C, Viallard JF, Virot JS, Benameur N, Zahr N, Yssel H, Godeau B, Amoura Z (2020) Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-217566 CrossRefPubMed

33.

Mihai C, Dobrota R, Schroder M, Garaiman A, Jordan S, Becker MO, Maurer B, Distler O (2020) COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD. Ann Rheum Dis 79:668–669. https://doi.org/10.1136/annrheumdis-2020-217442 CrossRefPubMed

34.

Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C (2020) Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 79:667–668. https://doi.org/10.1136/annrheumdis-2020-217424 CrossRefPubMed

35.

Song J, Kang S, Choi SW, Seo KW, Lee S, So MW, Lim DH (2020) Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs. Rheumatol Int. https://doi.org/10.1007/s00296-020-04584-7 CrossRefPubMedPubMedCentral

36.

Damiani G, Pacifico A, Bragazzi NL, Malagoli P (2020) Biologics increase the risk of SARS- CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during RED-ZONE declaration. Dermatol Ther. https://doi.org/10.1111/dth.13475 CrossRefPubMedPubMedCentral

37.

Dousa KM, Malavade SS, Furin J, Gripshover B, Hatszegi M, Hojat L, Saade E, Salata RA (2020) SARS-CoV-2 infection in a patient on chronic hydroxychloroquine therapy: implications for prophylaxis. IDCases. https://doi.org/10.1016/j.idcr.2020.e00778 CrossRefPubMedPubMedCentral

38.

Duret PM, Sebbag E, Mallick A, Gravier S, Spielmann L, Messer L (2020) Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-217362 CrossRefPubMed

39.

Emmi G, Bettiol A, Mattioli I, Silvestri E, Di Scala G, Urban ML, Vaglio A, Prisco D (2020) SARS-CoV-2 infection among patients with systemic autoimmune diseases. Autoimmun Rev. https://doi.org/10.1016/j.autrev.2020.102575 CrossRefPubMedPubMedCentral

40.

Favalli EG, Ingegnoli F, Cimaz R, Caporali R (2020) What is the true incidence of COVID-19 in patients with rheumatic diseases? Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-217615 CrossRefPubMed

41.

Konig MF, Kim AH, Scheetz MH, Graef ER, Liew JW, Simard J, Machado PM, Gianfrancesco M, Yazdany J, Langguth D, Robinson PC, Alliance C-GR (2020) Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-217690 CrossRefPubMed

42.

Moutsopoulos HM (2020) Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-217562 CrossRefPubMed

43.

Tomelleri A, Sartorelli S, Campochiaro C, Baldissera EM, Dagna L (2020) Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-217600 CrossRefPubMed

44.

Garg S, Kim L, Whitaker M, O'Halloran A, Cummings C, Holstein R, Prill M, Chai SJ, Kirley PD, Alden NB, Kawasaki B, Yousey-Hindes K, Niccolai L, Anderson EJ, Openo KP, Weigel A, Monroe ML, Ryan P, Henderson J, Kim S, Como-Sabetti K, Lynfield R, Sosin D, Torres S, Muse A, Bennett NM, Billing L, Sutton M, West N, Schaffner W, Talbot HK, Aquino C, George A, Budd A, Brammer L, Langley G, Hall AJ, Fry A (2020) Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 States, March 1–30, 2020. MMWR Morb Mortal Wkly Rep 69:458–464. https://doi.org/10.15585/mmwr.mm6915e3 CrossRefPubMedPubMedCentral

45.

Gendelman O, Amital H, Bragazzi NL, Watad A, Chodick G (2020) Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: insights from a large healthcare database analysis. Autoimmun Rev. https://doi.org/10.1016/j.autrev.2020.102566 CrossRefPubMedPubMedCentral

46.

Sirotich E, Dillingham S, Grainger R, Hausmann JS, Committee C-GRAS (2020) Capturing patient-reported outcomes during the COVID-19 pandemic: development of the COVID-19 global rheumatology alliance patient experience survey. Arthritis Care Res (Hoboken). https://doi.org/10.1002/acr.24257 CrossRef

47.

Xu B, Fan CY, Wang AL, Zou YL, Yu YH, He C, Xia WG, Zhang JX, Miao Q (2020) Suppressed T cell-mediated immunity in patients with COVID-19: a clinical retrospective study in Wuhan, China. J Infect. https://doi.org/10.1016/j.jinf.2020.04.012 CrossRefPubMedPubMedCentral

48.

Lee PI, Hu YL, Chen PY, Huang YC, Hsueh PR (2020) Are children less susceptible to COVID-19? J Microbiol Immunol Infect. https://doi.org/10.1016/j.jmii.2020.02.011 CrossRefPubMedPubMedCentral

49.

Brodin P (2020) Why is COVID-19 so mild in children? Acta Paediatr. https://doi.org/10.1111/apa.15271 CrossRefPubMed

50.

Liu Y, Yan LM, Wan L, Xiang TX, Le A, Liu JM, Peiris M, Poon LLM, Zhang W (2020) Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis. https://doi.org/10.1016/S1473-3099(20)30232-2 CrossRefPubMedPubMedCentral

51.

Nickbakhsh S, Mair C, Matthews L, Reeve R, Johnson PCD, Thorburn F, von Wissmann B, Reynolds A, McMenamin J, Gunson RN, Murcia PR (2019) Virus-virus interactions impact the population dynamics of influenza and the common cold. Proc Natl Acad Sci USA. https://doi.org/10.1073/pnas.1911083116 CrossRefPubMedPubMedCentral

52.

Carsetti R, Quintarelli C, Quinti I, Piano Mortari E, Zumla A, Ippolito G, Locatelli F (2020) The immune system of children: the key to understanding SARS-CoV-2 susceptibility? The Lancet Child & Adolescent Health. https://doi.org/10.1016/S2352-4642(20)30135-8 CrossRef

53.

Chen J JQ, Xia X, Liu K, Yu Z, Tao W, Gang W, Han J-D J (2020) Individual variation of the SARS-CoV2 receptor ACE2 gene expression and regulation. Preprints:2020030191

54.

Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, Zhang W, Wang Y, Bao S, Li Y, Wu C, Liu H, Liu D, Shao J, Peng X, Yang Y, Liu Z, Xiang Y, Zhang F, Silva RM, Pinkerton KE, Shen K, Xiao H, Xu S, Wong GWK, Chinese Pediatric Novel Coronavirus Study T (2020) SARS-CoV-2 infection in children. N Engl J Med 382:1663–1665. https://doi.org/10.1056/NEJMc2005073 CrossRef

55.

Roberts L (2020) Pandemic brings mass vaccinations to a halt. Science 368:116–117. https://doi.org/10.1126/science.368.6487.116 CrossRefPubMed

56.

She J, Liu L, Liu W (2020) COVID-19 epidemic: disease characteristics in children. J Med Virol. https://doi.org/10.1002/jmv.25807 CrossRefPubMedPubMedCentral

57.

Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, Li J, Zhao D, Xu D, Gong Q, Liao J, Yang H, Hou W, Zhang Y (2020) Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet 395:809–815. https://doi.org/10.1016/S0140-6736(20)30360-3 CrossRefPubMedPubMedCentral

58.

Netea MG, Joosten LA, Latz E, Mills KH, Natoli G, Stunnenberg HG, O'Neill LA, Xavier RJ (2016) Trained immunity: a program of innate immune memory in health and disease. Science 352:1098. https://doi.org/10.1126/science.aaf1098 CrossRef

59.

Miller A, Reandelar MJ, Fasciglione K, Roumenova V, Li Y, Otazu GH (2020) Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. medRxiv. https://doi.org/10.1101/2020.03.24.20042937 CrossRefPubMedPubMedCentral

60.

Moorlag S, Arts RJW, van Crevel R, Netea MG (2019) Non-specific effects of BCG vaccine on viral infections. Clin Microbiol Infect 25:1473–1478. https://doi.org/10.1016/j.cmi.2019.04.020 CrossRefPubMed

61.

Arts RJW, Moorlag S, Novakovic B, Li Y, Wang SY, Oosting M, Kumar V, Xavier RJ, Wijmenga C, Joosten LAB, Reusken C, Benn CS, Aaby P, Koopmans MP, Stunnenberg HG, van Crevel R, Netea MG (2018) BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. Cell Host Microbe 23(89–100):e105. https://doi.org/10.1016/j.chom.2017.12.010 CrossRef

62.

Berg RE, Cordes CJ, Forman J (2002) Contribution of CD8+ T cells to innate immunity: IFN-gamma secretion induced by IL-12 and IL-18. Eur J Immunol 32:2807–2816. https://doi.org/10.1002/1521-4141(2002010)32:10<2807:AID-IMMU2807>3.0.CO;2-0 CrossRefPubMed

63.

Berg RE, Crossley E, Murray S, Forman J (2003) Memory CD8+ T cells provide innate immune protection against Listeria monocytogenes in the absence of cognate antigen. J Exp Med 198:1583–1593. https://doi.org/10.1084/jem.20031051 CrossRefPubMedPubMedCentral

64.

Lertmemongkolchai G, Cai G, Hunter CA, Bancroft GJ (2001) Bystander activation of CD8+ T cells contributes to the rapid production of IFN-gamma in response to bacterial pathogens. J Immunol 166:1097–1105. https://doi.org/10.4049/jimmunol.166.2.1097 CrossRefPubMed

65.

Mathurin KS, Martens GW, Kornfeld H, Welsh RM (2009) CD4 T-cell-mediated heterologous immunity between mycobacteria and poxviruses. J Virol 83:3528–3539. https://doi.org/10.1128/JVI.02393-08 CrossRefPubMedPubMedCentral

66.

Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Ifrim DC, Saeed S, Jacobs C, van Loenhout J, de Jong D, Stunnenberg HG, Xavier RJ, van der Meer JW, van Crevel R, Netea MG (2012) Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci U S A 109:17537–17542. https://doi.org/10.1073/pnas.1202870109 CrossRefPubMedPubMedCentral

67.

Franklin R, Young A, Neumann B, Fernandez R, Joannides A, Reyahi A, Modis Y (2020) Homologous protein domains in SARS-CoV-2 and measles, mumps and rubella viruses: preliminary evidence that MMR vaccine might provide protection against COVID-19. medRxiv. https://doi.org/10.1101/2020.04.10.20053207 CrossRef

68.

Bianchi FP, Stefanizzi P, De Nitto S, Larocca AMV, Germinario C, Tafuri S (2020) Long-term immunogenicity of measles vaccine: an italian retrospective cohort study. J Infect Dis 221:721–728. https://doi.org/10.1093/infdis/jiz508 CrossRefPubMed

69.

Shanker V (2020) Measles immunization: worth considering containment strategy for SARS-CoV-2 global outbreak. Indian Pediatr 57:380CrossRefPubMed

70.

Atzeni F, Gerardi MC, Barilaro G, Masala IF, Benucci M, Sarzi-Puttini P (2018) Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review. Expert Rev Clin Immunol 14:69–82. https://doi.org/10.1080/1744666X.2018.1411190 CrossRefPubMed

71.

Malattia C, Martini A (2013) Paediatric-onset systemic lupus erythematosus. Best Pract Res Clin Rheumatol 27:351–362. https://doi.org/10.1016/j.berh.2013.07.007 CrossRefPubMed

72.

Ravelli A, Davi S, Minoia F, Martini A, Cron RQ (2015) Macrophage activation syndrome. Hematol Oncol Clin North Am 29:927–941. https://doi.org/10.1016/j.hoc.2015.06.010 CrossRefPubMed

73.

Cron RQ, Chatham WW (2020) The rheumatologist's role in COVID-19. J Rheumatol. https://doi.org/10.3899/jrheum.200334 CrossRefPubMed

74.

Cron RQ, Davi S, Minoia F, Ravelli A (2015) Clinical features and correct diagnosis of macrophage activation syndrome. Expert Rev Clin Immunol 11:1043–1053. https://doi.org/10.1586/1744666X.2015.1058159 CrossRefPubMed

75.

Rodriguez-Morales AJ, Cardona-Ospina JA, Gutierrez-Ocampo E, Villamizar-Pena R, Holguin-Rivera Y, Escalera-Antezana JP, Alvarado-Arnez LE, Bonilla-Aldana DK, Franco-Paredes C, Henao-Martinez AF, Paniz-Mondolfi A, Lagos-Grisales GJ, Ramirez-Vallejo E, Suarez JA, Zambrano LI, Villamil-Gomez WE, Balbin-Ramon GJ, Rabaan AA, Harapan H, Dhama K, Nishiura H, Kataoka H, Ahmad T, Sah R (2020) Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis. https://doi.org/10.1016/j.tmaid.2020.101623 CrossRefPubMedPubMedCentral

76.

Zhan J, Deng R, Tang J, Zhang B, Tang Y, Wang JK, Li F, Anderson VM, McNutt MA, Gu J (2006) The spleen as a target in severe acute respiratory syndrome. FASEB J 20:2321–2328. https://doi.org/10.1096/fj.06-6324com CrossRefPubMed

77.

Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, Janka G (2007) HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48:124–131. https://doi.org/10.1002/pbc.21039 CrossRefPubMed

78.

Barton LM, Duval EJ, Stroberg E, Ghosh S, Mukhopadhyay S (2020) COVID-19 autopsies, Oklahoma, USA. Am J Clin Pathol. https://doi.org/10.1093/ajcp/aqaa062 CrossRefPubMed

79.

Menter T, Haslbauer JD, Nienhold R, Savic S, Hopfer H, Deigendesch N, Frank S, Turek D, Willi N, Pargger H, Bassetti S, Leuppi JD, Cathomas G, Tolnay M, Mertz KD, Tzankov A (2020) Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction. Histopathology. https://doi.org/10.1111/his.14134 CrossRefPubMedPubMedCentral

80.

Bouaziz JD, Duong T, Jachiet M, Velter C, Lestang P, Cassius C, Arsouze A, Domergue Than Trong E, Bagot M, Begon E, Sulimovic L, Rybojad M (2020) Vascular skin symptoms in COVID-19: a french observational study. J Eur Acad Dermatol Venereol. https://doi.org/10.1111/jdv.16544 CrossRefPubMedPubMedCentral

81.

Sonmez HE, Karaaslan C, de Jesus AA, Batu ED, Anlar B, Sozeri B, Bilginer Y, Karaguzel D, Cagdas Ayvaz D, Tezcan I, Goldbach-Mansky R, Ozen S (2020) A clinical score to guide in decision making for monogenic type I IFNopathies. Pediatr Res 87:745–752. https://doi.org/10.1038/s41390-019-0614-2 CrossRefPubMed

82.

Basatneh R, Vlahovic TC (2020) Addressing the question of dermatologic manifestations of SARS-CoV-2 infection in the lower extremities: a closer look at the available data and its implications. J Am Podiatr Med Assoc. https://doi.org/10.7547/20-074 CrossRefPubMed

83.

Fernandez-Nieto D, Jimenez-Cauhe J, Suarez-Valle A, Moreno-Arrones OM, Saceda-Corralo D, Arana-Raja A, Ortega-Quijano D (2020) Characterization of acute acro-ischemic lesions in non-hospitalized patients: a case series of 132 patients during the COVID-19 outbreak. J Am Acad Dermatol. https://doi.org/10.1016/j.jaad.2020.04.093 CrossRefPubMedPubMedCentral

84.

Zhang Y, Cao W, Xiao M, Li YJ, Yang Y, Zhao J, Zhou X, Jiang W, Zhao YQ, Zhang SY, Li TS (2020) Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia. Zhonghua Xue Ye Xue Za Zhi 41:E006. https://doi.org/10.3760/cma.j.issn.0253-2727.2020.0006 CrossRefPubMed

85.

Batu ED, Karadag O, Taskiran EZ, Kalyoncu U, Aksentijevich I, Alikasifoglu M, Ozen S (2015) A case series of adenosine deaminase 2-deficient patients emphasizing treatment and genotype-phenotype correlations. J Rheumatol 42:1532–1534. https://doi.org/10.3899/jrheum.150024 CrossRefPubMed

86.

Ozen S, Batu ED, Taskiran EZ, Ozkara HA, Unal S, Guleray N, Erden A, Karadag O, Gumruk F, Cetin M, Sonmez HE, Bilginer Y, Ayvaz DC, Tezcan I (2020) A Monogenic disease with a variety of phenotypes: deficiency of adenosine deaminase 2. J Rheumatol 47:117–125. https://doi.org/10.3899/jrheum.181384 CrossRefPubMed

87.

Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, Chen H, Ding X, Zhao H, Zhang H, Wang C, Zhao J, Sun X, Tian R, Wu W, Wu D, Ma J, Chen Y, Zhang D, Xie J, Yan X, Zhou X, Liu Z, Wang J, Du B, Qin Y, Gao P, Qin X, Xu Y, Zhang W, Li T, Zhang F, Zhao Y, Li Y, Zhang S (2020) Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med 382:e38. https://doi.org/10.1056/NEJMc2007575 CrossRefPubMed

88.

Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P (2020) Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. https://doi.org/10.1016/S0140-6736(20)31094-1 CrossRefPubMedPubMedCentral

89.

Li Y, Zheng Q, Zou L, Wu J, Guo L, Teng L, Zheng R, Jung LKL, Lu M (2019) Kawasaki disease shock syndrome: clinical characteristics and possible use of IL-6, IL-10 and IFN-gamma as biomarkers for early recognition. Pediatr Rheumatol Online J 17:1. https://doi.org/10.1186/s12969-018-0303-4 CrossRefPubMedPubMedCentral

90.

Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, De Leacy RA, Shigematsu T, Ladner TR, Yaeger KA, Skliut M, Weinberger J, Dangayach NS, Bederson JB, Tuhrim S, Fifi JT (2020) Large-vessel stroke as a presenting feature of Covid-19 in the Young. N Engl J Med. https://doi.org/10.1056/NEJMc2009787 CrossRefPubMedPubMedCentral

91.

Lachmann HJ (2017) Periodic fever syndromes. Best Pract Res Clin Rheumatol 31:596–609. https://doi.org/10.1016/j.berh.2017.12.001 CrossRefPubMed

92.

Ozen S, Batu ED, Demir S (2017) Familial Mediterranean fever: recent developments in pathogenesis and new recommendations for management. Front Immunol 8:253. https://doi.org/10.3389/fimmu.2017.00253 CrossRefPubMedPubMedCentral

93.

Cattan D (2005) MEFV mutation carriers and diseases other than familial Mediterranean fever: proved and non-proved associations; putative biological advantage. Curr Drug Targets Inflamm Allergy 4:105–112. https://doi.org/10.2174/1568010053622948 CrossRefPubMed

94.

Chung LK, Park YH, Zheng Y, Brodsky IE, Hearing P, Kastner DL, Chae JJ, Bliska JB (2016) The yersinia virulence factor yopm hijacks host kinases to inhibit type III effector-triggered activation of the pyrin inflammasome. Cell Host Microbe 20:296–306. https://doi.org/10.1016/j.chom.2016.07.018 CrossRefPubMedPubMedCentral

95.

Chen IY, Moriyama M, Chang MF, Ichinohe T (2019) severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome. Front Microbiol 10:50. https://doi.org/10.3389/fmicb.2019.00050 CrossRefPubMedPubMedCentral

96.

Shi CS, Nabar NR, Huang NN, Kehrl JH (2019) SARS-coronavirus open reading frame-8b triggers intracellular stress pathways and activates NLRP3 inflammasomes. Cell Death Discov 5:101. https://doi.org/10.1038/s41420-019-0181-7 CrossRefPubMedPubMedCentral

97.

Zhang T, Du H, Feng S, Wu R, Chen T, Jiang J, Peng Y, Ye C, Fang R (2019) NLRP3/ASC/Caspase-1 axis and serine protease activity are involved in neutrophil IL-1beta processing during Streptococcus pneumoniae infection. Biochem Biophys Res Commun 513:675–680. https://doi.org/10.1016/j.bbrc.2019.04.004 CrossRefPubMed

98.

Walker UA, Hoffman HM, Williams R, Kuemmerle-Deschner J, Hawkins PN (2016) Brief report: severe inflammation following vaccination against Streptococcus pneumoniae in patients with cryopyrin-associated periodic syndromes. Arthritis Rheumatol 68:516–520. https://doi.org/10.1002/art.39482 CrossRefPubMed

99.

Vastert SJ, van Wijk R, D'Urbano LE, de Vooght KM, de Jager W, Ravelli A, Magni-Manzoni S, Insalaco A, Cortis E, van Solinge WW, Prakken BJ, Wulffraat NM, de Benedetti F, Kuis W (2010) Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford) 49:441–449. https://doi.org/10.1093/rheumatology/kep418 CrossRef

100.

Canna SW, de Jesus AA, Gouni S, Brooks SR, Marrero B, Liu Y, DiMattia MA, Zaal KJ, Sanchez GA, Kim H, Chapelle D, Plass N, Huang Y, Villarino AV, Biancotto A, Fleisher TA, Duncan JA, O'Shea JJ, Benseler S, Grom A, Deng Z, Laxer RM, Goldbach-Mansky R (2014) An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet 46:1140–1146. https://doi.org/10.1038/ng.3089 CrossRefPubMedPubMedCentral

101.

Sawalha AH, Zhao M, Coit P, Lu Q (2020) Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients. Clin Immunol 215:108410. https://doi.org/10.1016/j.clim.2020.108410 CrossRefPubMedPubMedCentral

102.

Ferro F, Elefante E, Baldini C, Bartoloni E, Puxeddu I, Talarico R, Mosca M, Bombardieri S (2020) COVID-19: the new challenge for rheumatologists. Clin Exp Rheumatol 38:175–180PubMed

103.

Au K, Reed G, Curtis JR, Kremer JM, Greenberg JD, Strand V, Furst DE, Investigators C (2011) High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis 70:785–791. https://doi.org/10.1136/ard.2010.128637 CrossRefPubMed

104.

Danza A, Ruiz-Irastorza G (2013) Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. Lupus 22:1286–1294. https://doi.org/10.1177/0961203313493032 CrossRefPubMed

105.

Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, Leist SR, Pyrc K, Feng JY, Trantcheva I, Bannister R, Park Y, Babusis D, Clarke MO, Mackman RL, Spahn JE, Palmiotti CA, Siegel D, Ray AS, Cihlar T, Jordan R, Denison MR, Baric RS (2017) Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aal3653 CrossRefPubMedPubMedCentral

106.

Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, Nicastri E, Oda R, Yo K, Quiros-Roldan E, Studemeister A, Redinski J, Ahmed S, Bernett J, Chelliah D, Chen D, Chihara S, Cohen SH, Cunningham J, D'Arminio Monforte A, Ismail S, Kato H, Lapadula G, L'Her E, Maeno T, Majumder S, Massari M, Mora-Rillo M, Mutoh Y, Nguyen D, Verweij E, Zoufaly A, Osinusi AO, DeZure A, Zhao Y, Zhong L, Chokkalingam A, Elboudwarej E, Telep L, Timbs L, Henne I, Sellers S, Cao H, Tan SK, Winterbourne L, Desai P, Mera R, Gaggar A, Myers RP, Brainard DM, Childs R, Flanigan T (2020) Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. https://doi.org/10.1056/NEJMoa2007016 CrossRefPubMedPubMedCentral

107.

Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, Wang K, Lu Y, Li H, Wang S, Ruan S, Yang C, Mei C, Wang Y, Ding D, Wu F, Tang X, Ye X, Ye Y, Liu B, Yang J, Yin W, Wang A, Fan G, Zhou F, Liu Z, Gu X, Xu J, Shang L, Zhang Y, Cao L, Guo T, Wan Y, Qin H, Jiang Y, Jaki T, Hayden FG, Horby PW, Cao B, Wang C (2020) Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. https://doi.org/10.1016/S0140-6736(20)31022-9 CrossRefPubMedPubMedCentral

108.

Yao TT, Qian JD, Zhu WY, Wang Y, Wang GQ (2020) A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option. J Med Virol. https://doi.org/10.1002/jmv.25729 CrossRefPubMedPubMedCentral

109.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C (2020) A trial of lopinavir–ritonavir in adults hospitalized with severe covid-19. N Engl J Med 382:1787–1799. https://doi.org/10.1056/NEJMoa2001282 CrossRefPubMed

110.

Little P (2020) Non-steroidal anti-inflammatory drugs and covid-19. BMJ 368:m1185. https://doi.org/10.1136/bmj.m1185 CrossRefPubMed

111.

Fang L, Karakiulakis G, Roth M (2020) Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 8:e21. https://doi.org/10.1016/S2213-2600(20)30116-8 CrossRefPubMedPubMedCentral

112.

Day M (2020) Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ 368:m1086. https://doi.org/10.1136/bmj.m1086 CrossRefPubMed

113.

Giollo A, Adami G, Gatti D, Idolazzi L, Rossini M (2020) Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID). Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-217598 CrossRefPubMed

114.

Le Bourgeois M, Ferroni A, Leruez-Ville M, Varon E, Thumerelle C, Bremont F, Fayon MJ, Delacourt C, Ligier C, Watier L, Guillemot D, Children ANA-iD, Childhood Empyema Study G (2016) Nonsteroidal anti-inflammatory drug without antibiotics for acute viral infection increases the empyema risk in children: a matched case–control study. J Pediatr 175(47–53):e43. https://doi.org/10.1016/j.jpeds.2016.05.025 CrossRef

115.

Voiriot G, Philippot Q, Elabbadi A, Elbim C, Chalumeau M, Fartoukh M (2019) Risks related to the use of non-steroidal anti-inflammatory drugs in community-acquired pneumonia in adult and pediatric patients. J Clin Med. https://doi.org/10.3390/jcm8060786 CrossRefPubMedPubMedCentral

116.

Batu ED (2019) Glucocorticoid treatment in juvenile idiopathic arthritis. Rheumatol Int 39:13–27. https://doi.org/10.1007/s00296-018-4168-0 CrossRefPubMed

117.

Chan ED, Chan MM, Chan MM, Marik PE (2020) Use of glucocorticoids in the critical care setting: science and clinical evidence. Pharmacol Ther 206:107428. https://doi.org/10.1016/j.pharmthera.2019.107428 CrossRefPubMed

118.

Chen RC, Tang XP, Tan SY, Liang BL, Wan ZY, Fang JQ, Zhong N (2006) Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest 129:1441–1452. https://doi.org/10.1378/chest.129.6.1441 CrossRefPubMed

119.

Ho JC, Ooi GC, Mok TY, Chan JW, Hung I, Lam B, Wong PC, Li PC, Ho PL, Lam WK, Ng CK, Ip MS, Lai KN, Chan-Yeung M, Tsang KW (2003) High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med 168:1449–1456. https://doi.org/10.1164/rccm.200306-766OC CrossRefPubMed

120.

Yam LY, Lau AC, Lai FY, Shung E, Chan J, Wong V, Hong Kong Hospital Authority SCG (2007) Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong. J Infect 54:28–39. https://doi.org/10.1016/j.jinf.2006.01.005 CrossRef

121.

Auyeung TW, Lee JS, Lai WK, Choi CH, Lee HK, Lee JS, Li PC, Lok KH, Ng YY, Wong WM, Yeung YM (2005) The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study. J Infect 51:98–102. https://doi.org/10.1016/j.jinf.2004.09.008 CrossRefPubMed

122.

Tsai MJ, Yang KY, Chan MC, Kao KC, Wang HC, Perng WC, Wu CL, Liang SJ, Fang WF, Tsai JR, Chang WA, Chien YC, Chen WC, Hu HC, Lin CY, Chao WC, Sheu CC, for Taiwan Severe Influenza Research Consortium I (2020) Impact of corticosteroid treatment on clinical outcomes of influenza-associated ARDS: a nationwide multicenter study. Ann Intensive Care 10:26. https://doi.org/10.1186/s13613-020-0642-4 CrossRef

123.

Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y (2020) Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. https://doi.org/10.1001/jamainternmed.2020.0994 CrossRefPubMedPubMedCentral

124.

Wang Y, Jiang W, He Q, Wang C, Wang B, Zhou P, Dong N, Tong Q (2020) A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia. Signal Transduct Target Ther 5:57. https://doi.org/10.1038/s41392-020-0158-2 CrossRefPubMedPubMedCentral

125.

Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, Boletis J, Cervera R, Dorner T, Doria A, Ferrario F, Floege J, Houssiau FA, Ioannidis JP, Isenberg DA, Kallenberg CG, Lightstone L, Marks SD, Martini A, Moroni G, Neumann I, Praga M, Schneider M, Starra A, Tesar V, Vasconcelos C, van Vollenhoven RF, Zakharova H, Haubitz M, Gordon C, Jayne D, Boumpas DT, European League Against R, European Renal Association-European D, Transplant A (2012) Joint European league against rheumatism and European Renal association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 71:1771–1782. https://doi.org/10.1136/annrheumdis-2012-201940 CrossRefPubMed

126.

Scuccimarri R, Sutton E, Fitzcharles MA (2020) Hydroxychloroquine: a potential ethical dilemma for rheumatologists during the COVID-19 pandemic. J Rheumatol. https://doi.org/10.3899/jrheum.200369 CrossRefPubMed

127.

Shah S, Das S, Jain A, Misra DP, Negi VS (2020) A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19). Int J Rheum Dis. https://doi.org/10.1111/1756-185X.13842 CrossRefPubMedPubMedCentral

128.

Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Dupont HT, Honore S, Colson P, Chabriere E, La Scola B, Rolain JM, Brouqui P, Raoult D (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. https://doi.org/10.1016/j.ijantimicag.2020.105949 CrossRefPubMedPubMedCentral

129.

Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF, American Academy of O (2016) Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 123:1386–1394. https://doi.org/10.1016/j.ophtha.2016.01.058 CrossRefPubMed

130.

O'Laughlin JP, Mehta PH, Wong BC (2016) Life threatening severe QTc prolongation in patient with systemic lupus erythematosus due to hydroxychloroquine. Case Rep Cardiol 2016:4626279. https://doi.org/10.1155/2016/4626279 CrossRefPubMedPubMedCentral

131.

Mason JW (2017) Antimicrobials and QT prolongation. J Antimicrob Chemother 72:1272–1274. https://doi.org/10.1093/jac/dkw591 CrossRefPubMed

132.

Saleh M, Gabriels J, Chang D, Kim BS, Mansoor A, Mahmood E, Makker P, Ismail H, Goldner B, Willner J, Beldner S, Mitra R, John R, Chinitz J, Skipitaris N, Mountantonakis S, Epstein LM (2020) The effect of chloroquine, hydroxychloroquine and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection. Circ Arrhythm Electrophysiol. https://doi.org/10.1161/CIRCEP.120.008662 CrossRefPubMedPubMedCentral

133.

Miserocchi E, Giuffre C, Cornalba M, Pontikaki I, Cimaz R (2020) JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis. Clin Rheumatol 39:847–851. https://doi.org/10.1007/s10067-019-04875-w CrossRefPubMed

134.

Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, Schalm S, Murias S, Dare JA, Brown D, Stone DL, Gao L, Klausmeier T, Foell D, de Jesus AA, Chapelle DC, Kim H, Dill S, Colbert RA, Failla L, Kost B, O'Brien M, Reynolds JC, Folio LR, Calvo KR, Paul SM, Weir N, Brofferio A, Soldatos A, Biancotto A, Cowen EW, Digiovanna JJ, Gadina M, Lipton AJ, Hadigan C, Holland SM, Fontana J, Alawad AS, Brown RJ, Rother KI, Heller T, Brooks KM, Kumar P, Brooks SR, Waldman M, Singh HK, Nickeleit V, Silk M, Prakash A, Janes JM, Ozen S, Wakim PG, Brogan PA, Macias WL, Goldbach-Mansky R (2018) JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest 128:3041–3052. https://doi.org/10.1172/JCI98814 CrossRefPubMedPubMedCentral

135.

Favalli EG, Biggioggero M, Maioli G, Caporali R (2020) Baricitinib for COVID-19: a suitable treatment? Lancet Infect Dis. https://doi.org/10.1016/S1473-3099(20)30262-0 CrossRefPubMedPubMedCentral

136.

Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, Stebbing J (2020) Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 395:e30–e31. https://doi.org/10.1016/S0140-6736(20)30304-4 CrossRefPubMedPubMedCentral

137.

Fensterl V, Sen GC (2009) Interferons and viral infections. BioFactors 35:14–20. https://doi.org/10.1002/biof.6 CrossRefPubMed

138.

Smolen JS, Genovese MC, Takeuchi T, Hyslop DL, Macias WL, Rooney T, Chen L, Dickson CL, Riddle Camp J, Cardillo TE, Ishii T, Winthrop KL (2019) Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. J Rheumatol 46:7–18. https://doi.org/10.3899/jrheum.171361 CrossRefPubMed

139.

Ruan Q, Yang K, Wang W, Jiang L, Song J (2020) Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan China. Intensive Care Med. https://doi.org/10.1007/s00134-020-05991-x CrossRefPubMedPubMedCentral

140.

Alattar R, Ibrahim TBH, Shaar SH, Abdalla S, Shukri K, Daghfal JN, Khatib MY, Aboukamar M, Abukhattab M, Alsoub HA, Almaslamani MA, Omrani AS (2020) Tocilizumab for the treatment of severe coronavirus disease 2019. J Med Virol. https://doi.org/10.1002/jmv.25964 CrossRefPubMedPubMedCentral

141.

Alzghari SK, Acuna VS (2020) Supportive treatment with tocilizumab for COVID-19: a systematic review. J Clin Virol 127:104380. https://doi.org/10.1016/j.jcv.2020.104380 CrossRefPubMedPubMedCentral

142.

Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, Franceschini F, Foca E, Andreoli L, Latronico N, Brescia International R, Training HUB (2020) Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev 10:2568. https://doi.org/10.1016/j.autrev.2020.102568 CrossRef

143.

Klopfenstein T, Zayet S, Lohse A, Balblanc JC, Badie J, Royer PY, Toko L, Mezher C, Kadiane-Oussou NJ, Bossert M, Bozgan AM, Charpentier A, Roux MF, Contreras R, Mazurier I, Dussert P, Gendrin V, Conrozier T (2020) Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Med Mal Infect. https://doi.org/10.1016/j.medmal.2020.05.001 CrossRefPubMedPubMedCentral

144.

Sciascia S, Apra F, Baffa A, Baldovino S, Boaro D, Boero R, Bonora S, Calcagno A, Cecchi I, Cinnirella G, Converso M, Cozzi M, Crosasso P, De Iaco F, Di Perri G, Eandi M, Fenoglio R, Giusti M, Imperiale D, Imperiale G, Livigni S, Manno E, Massara C, Milone V, Natale G, Navarra M, Oddone V, Osella S, Piccioni P, Radin M, Roccatello D, Rossi D (2020) Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin Exp Rheumatol

145.

Balasubramanian S, Nagendran TM, Ramachandran B, Ramanan AV (2020) Hyper-inflammatory syndrome in a child with COVID-19 treated successfully with intravenous immunoglobulin and tocilizumab. Indian Pediatr

146.

Odievre MH, de Marcellus C, Ducou Le Pointe H, Allali S, Romain AS, Youn J, Taytard J, Nathan N, Corvol H (2020) Dramatic improvement after Tocilizumab of a severe COVID-19 in a child with sickle cell disease and acute chest syndrome. Am J Hematol. https://doi.org/10.1002/ajh.25855 CrossRefPubMedPubMedCentral

147.

Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, Oltolini C, Castiglioni B, Tassan Din C, Boffini N, Tomelleri A, Farina N, Ruggeri A, Rovere-Querini P, Di Lucca G, Martinenghi S, Scotti R, Tresoldi M, Ciceri F, Landoni G, Zangrillo A, Scarpellini P, Dagna L (2020) Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. https://doi.org/10.1016/S2665-9913(20)30127-2 CrossRefPubMedPubMedCentral

148.

Lythgoe MP, Middleton P (2020) Ongoing clinical trials for the management of the COVID-19 pandemic. Trends Pharmacol Sci. https://doi.org/10.1016/j.tips.2020.03.006 CrossRefPubMedPubMedCentral

149.

Costi S, Caporali R, Cimaz R (2020) Dealing with COVID-19 in a pediatric rheumatology unit in Italy. Paediatr Drugs. https://doi.org/10.1007/s40272-020-00395-2 CrossRefPubMedPubMedCentral

150.

Gasparyan AY, Misra DP, Yessirkepov M, Zimba O (2020) Perspectives of immune therapy in coronavirus disease 2019. J Korean Med Sci 35:e176. https://doi.org/10.3346/jkms.2020.35.e176 CrossRefPubMedPubMedCentral

151.

Ahn JY, Sohn Y, Lee SH, Cho Y, Hyun JH, Baek YJ, Jeong SJ, Kim JH, Ku NS, Yeom JS, Roh J, Ahn MY, Chin BS, Kim YS, Lee H, Yong D, Kim HO, Kim S, Choi JY (2020) Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. J Korean Med Sci 35:e149. https://doi.org/10.3346/jkms.2020.35.e149 CrossRefPubMedPubMedCentral

152.

Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, Peng C, Yuan M, Huang J, Wang Z, Yu J, Gao X, Wang D, Yu X, Li L, Zhang J, Wu X, Li B, Xu Y, Chen W, Peng Y, Hu Y, Lin L, Liu X, Huang S, Zhou Z, Zhang L, Wang Y, Zhang Z, Deng K, Xia Z, Gong Q, Zhang W, Zheng X, Liu Y, Yang H, Zhou D, Yu D, Hou J, Shi Z, Chen S, Chen Z, Zhang X, Yang X (2020) Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA 117:9490–9496. https://doi.org/10.1073/pnas.2004168117 CrossRefPubMedPubMedCentral

153.

Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, Wei J, Xiao H, Yang Y, Qu J, Qing L, Chen L, Xu Z, Peng L, Li Y, Zheng H, Chen F, Huang K, Jiang Y, Liu D, Zhang Z, Liu Y, Liu L (2020) Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. https://doi.org/10.1001/jama.2020.4783 CrossRefPubMedPubMedCentral

154.

Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, Xia X, Lv T (2020) Treatment with convalescent plasma for COVID-19 patients in Wuhan. China. J Med Virol. https://doi.org/10.1002/jmv.25882 CrossRefPubMed

155.

Zhang B, Liu S, Tan T, Huang W, Dong Y, Chen L, Chen Q, Zhang L, Zhong Q, Zhang X, Zou Y, Zhang S (2020) Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection. Chest. https://doi.org/10.1016/j.chest.2020.03.039 CrossRefPubMedPubMedCentral

156.

Filocamo G, Minoia F, Carbogno S, Costi S, Romano M, Cimaz R, Pediatric Rheumatology Group of the Milan A (2020) Absence of severe complications from SARS-CoV-2 infection in children with rheumatic diseases treated with biologic drugs. J Rheumatol. https://doi.org/10.3899/jrheum.200483 CrossRef

157.

Sarzi-Puttini P, Marotto D, Antivalle M, Salaffi F, Atzeni F, Maconi G, Monteleone G, Rizzardini G, Antinori S, Galli M, Ardizzone S (2020) How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion. Autoimmun Rev. https://doi.org/10.1016/j.autrev.2020.102574 CrossRefPubMedPubMedCentral

158.

Gupta L, Misra DP, Agarwal V, Balan S, Agarwal V (2020) Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology practitioners from India. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-217509 CrossRefPubMed

Title: Implications of COVID-19 in pediatric rheumatology
Authors: Ezgi Deniz Batu
Seza Özen
Publication date: 01-08-2020
Publisher: Springer Berlin Heidelberg
Keywords: Systemic Lupus Erythematosus
SARS-CoV-2
COVID-19
Cytokines
Hydroxychloroquine
Familial Mediterranean Fever
Pediatric Rheumatology
Published in: Rheumatology International / Issue 8/2020
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-020-04612-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2020

Targeting the immunology of coronavirus disease-19: synchronization creates symphony

Crystalglobulinemia manifested as acute renal failure and thrombotic vasculopathy

The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk

Provisional seven-item criteria for the diagnosis of polyarteritis nodosa

Peripheral neuropathy and health-related quality of life in patients with primary Sjögren’s syndrome: a preliminary report

Disease activity and patient-reported outcomes in patients with rheumatoid arthritis and Sjögren’s syndrome enrolled in a large observational US registry

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage